<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="109078"><DrugName>JAB-3068</DrugName><DrugSynonyms><Name><Value>JAB-3068</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SHP2 inhibitor (cancer), Jacobio Pharmaceuticals</Value></Name></DrugSynonyms><CompanyOriginator id="1157883">Jacobio Pharmaceuticals Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1157883">Jacobio Pharmaceuticals Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1157883" type="Company"><TargetEntity id="5063750263" type="organizationId">Jacobio Pharmaceuticals Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1011" type="ciIndication"><TargetEntity id="C15" type="ICD10"></TargetEntity><TargetEntity id="150" type="ICD9"></TargetEntity><TargetEntity id="10061882" type="MEDDRA"></TargetEntity><TargetEntity id="D004938" type="MeSH"></TargetEntity><TargetEntity id="-1694229607" type="omicsDisease"></TargetEntity><TargetEntity id="598" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="10327" type="Action"><TargetEntity id="2327" type="Mechanism">Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="PTGT-02444" type="ciTarget"><TargetEntity id="124312856657813" type="siTarget">Tyrosine-protein phosphatase non-receptor type 11</TargetEntity><TargetEntity id="699" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1011">Esophagus tumor</Indication><Indication id="3713">Advanced solid tumor</Indication></IndicationsPrimary><ActionsPrimary><Action id="10327">Protein tyrosine phosphatase-2C inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-24T01:46:16.000Z</LastModificationDate><ChangeDateLast>2019-04-25T00:00:00.000Z</ChangeDateLast><AddedDate>2018-01-17T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1157883" linkType="Company"&gt;Jacobio&lt;/ulink&gt; is developing JAB-3068, a SHP2 (PTPN11) inhibitor, as a tablet formulation, for the potential oral treatment of advanced solid tumors, including esophageal cancer [&lt;ulink linkID="1997685" linkType="Reference"&gt;1997685&lt;/ulink&gt;], [&lt;ulink linkID="2128041" linkType="Reference"&gt;2128041&lt;/ulink&gt;], [&lt;ulink linkID="2128045" linkType="Reference"&gt;2128045&lt;/ulink&gt;]. In April 2018, a phase I trial was initiated in the US for advanced solid tumors [&lt;ulink linkID="2044230" linkType="Reference"&gt;2044230&lt;/ulink&gt;]. In November 2018, a phase I trial was initiated  in China for advanced solid tumors [&lt;ulink linkID="2101496" linkType="Reference"&gt;2101496&lt;/ulink&gt;]. In May 2019, approval to conduct a phase IIa trial was obtained in the US [&lt;ulink linkID="2166851" linkType="Reference"&gt;2166851&lt;/ulink&gt;]; by June 2019, phase II trials were expected to initiate in 2019 in the US and China [&lt;ulink linkID="2166861" linkType="Reference"&gt;2166861&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In February 2019, the US FDA granted Orphan designation to a SHP2 inhibitor, for treatment of esophageal cancer [&lt;ulink linkID="2128041" linkType="Reference"&gt;2128041&lt;/ulink&gt;], [&lt;ulink linkID="2145063" linkType="Reference"&gt;2145063&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In January 2018, the company was developing the tablet as a class 1 chemical drug in China [&lt;ulink linkID="1997685" linkType="Reference"&gt;1997685&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2019, approval to conduct a phase IIa trial was obtained in the US [&lt;ulink linkID="2166851" linkType="Reference"&gt;2166851&lt;/ulink&gt;]; by June 2019, phase II trials were expected to initiate in 2019 in the US and China [&lt;ulink linkID="2166861" linkType="Reference"&gt;2166861&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2018, an open-label, dose escalation, multi-center, phase  I trial (&lt;ulink linkID="343742" linkType="Protocol"&gt;NCT03565003&lt;/ulink&gt;; JAB-3068-02; &lt;ulink linkID="343742" linkType="Protocol"&gt;CTR20181038&lt;/ulink&gt;) was planned in China to evaluate the safety, tolerability, pharmacokinetics and to determine the maximum tolerated dose according to a 3+3 design and recommended phase II dose in patients (estimated n = 30) with advanced solid tumors; at that time, the trial was expected to initiate in October 2018 and to complete in May 2020. By November 2018, the trial was initiated [&lt;ulink linkID="2101493" linkType="Reference"&gt;2101493&lt;/ulink&gt;], [&lt;ulink linkID="2101496" linkType="Reference"&gt;2101496&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2018, a single-group, open-label, multicenter, dose-escalation, phase I trial (&lt;ulink linkID="338806" linkType="Protocol"&gt;NCT03518554&lt;/ulink&gt;; JAB-3068-01) was initiated in the US in patients (estimated n = 30) with  advanced solid tumors including non-small cell lung cancer, head and neck cancer, esophageal cancer and other metastatic solid tumors, to assess the safety, tolerability, PK and preliminary evidence of antitumor activity of JAB-3068. In June 2018, the completion of the trial was expected in April 2020 [&lt;ulink linkID="2044230" linkType="Reference"&gt;2044230&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2018, an IND application was filed in China [&lt;ulink linkID="1997685" linkType="Reference"&gt;1997685&lt;/ulink&gt;]; in June 2018, approval to conduct a clinical trial was obtained in China [&lt;ulink linkID="2101499" linkType="Reference"&gt;2101499&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2018, approval to conduct a clinical trial was obtained in the US [&lt;ulink linkID="2101499" linkType="Reference"&gt;2101499&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By June 2018, preclinical data showed that the drug had significant efficacy in anti-tumors and enhanced the  function of CD8+ T cells [&lt;ulink linkID="2101499" linkType="Reference"&gt;2101499&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1157883">Jacobio Pharmaceuticals Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1011">Esophagus tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-23T00:00:00.000Z</StatusDate><Source id="2044230" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1157883">Jacobio Pharmaceuticals Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-11-13T00:00:00.000Z</StatusDate><Source id="2101496" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1157883">Jacobio Pharmaceuticals Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-23T00:00:00.000Z</StatusDate><Source id="2044230" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1157883">Jacobio Pharmaceuticals Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-16T00:00:00.000Z</StatusDate><Source id="1997685" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1157883">Jacobio Pharmaceuticals Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="1011">Esophagus tumor</Indication><AwardedIndication>Treatment of esophageal cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-02-28T00:00:00.000Z</MileStoneDate><Source id="2128041" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-02444"><Name>Protein tyrosine phosphatase-2C</Name><SwissprotNumbers><Swissprot>P35235</Swissprot><Swissprot>P41499</Swissprot><Swissprot>Q06124</Swissprot><Swissprot>Q90687</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="3881938" number="WO-2017211303" title="Novel heterocyclic derivatives useful as SHP2 inhibitors"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jacobio Pharmaceuticals Co Ltd" id="1157883"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>